Celgene (NYSE:CELG) is a pharmaceutical company that develops and sells drugs to treat blood cancers. Its main drugs include Thalomid, which is used to treat multiple myeloma, a cancer of the plasma cell in blood; Revlimid, which is a first-line treatment for myelodysplastic syndrome (MDS); and a family of Ritalin drugs, which are used to treat Attention Deficit Disorder (ADHD). The company generated $2.6 billion in revenue and $777 million in net income in 2009.
However, Revlimid will face its stiffest competition yet when rival company Millemnium's new drug Velcade is approved for use in first-line treatment of multiple myeloma. Velcade has shown much greater efficacy as a first-line treatment in its clinical trials, surpassing the performance of Revlimid, which means it will compete fiercely with Revlimid after it receives FDA approval and enters the market.(Read more at Wikinvest )